Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

被引：0
|
作者：
Oh, D-Y. [1 ]
Meric-Bernstam, F. [2 ]
Makker, V. [3 ]
Oaknin, A. [4 ]
Banerjee, S. [5 ]
Gonzalez Martin, A. [6 ,7 ]
Jung, K. H. [8 ]
Lugowska, I. [9 ,10 ]
Manso, L. M. [11 ]
Manzano, A. [12 ]
Melichar, B. [13 ]
Siena, S. [14 ]
Stroyakovskiy, D. [15 ]
Fielding, A. [16 ]
Ma, Y. [17 ]
Puvvada, S. D.
Lee, J-Y. [18 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Vall dHebron Inst Oncol, Hosp Univ Vall dHebron, Gynaecol Canc Programme, Barcelona, Spain
[5] Royal Marsden NHS Fdn Trust & Inst Canc Res, Gynaecol Unit, London, England
[6] Univ Navarra, Canc Ctr Clin, Med Oncol Dept, Madrid, Spain
[7] Univ Navarra, Canc Ctr Clin, Programme Solid Tumours CIMA, Madrid, Spain
[8] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Unit, Warsaw, Poland
[10] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[11] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[12] Hosp Clin San Carlos, Dept Med Oncol, Expt Therapeut Canc UTEC, Madrid, Spain
[13] Palacky Univ, Univ Hosp, Dept Oncol, Med Sch, Olomouc, Czech Republic
[14] Univ Milan, Dept Oncol, Piazza Osped Maggiore, Milan, Italy
[15] Moscow City Oncol Hosp 62, Healthcare Dept, Moscow, Russia
[16] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[17] AstraZeneca, Oncol R&D, Cambridge, England
[18] Yonsei Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
74MO
引用
收藏
页码：S1494 / S1495
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
    Li, B. T.
    Meric-Bernstam, F.
    Bardia, A.
    Naito, Y.
    Siena, S.
    Aftimos, P. G.
    Anderson, I.
    Curigliano, G.
    De Miguel Luken, M. J.
    Kalra, M.
    Oh, D-Y.
    Park, J. O.
    Postel-Vinay, S.
    Rha, S. Y.
    Satoh, T.
    Spanggaard, I.
    Michelini, F.
    Smith, A.
    Machado, K. Kalil
    Saura Manich, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S460
  • [22] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
    Krop, Ian E.
    Wildiers, Hans
    Hurvitz, Sara A.
    Cortes, Javier
    Im, Seock-Ah
    Iwata, Hiroji
    Andre, Fabrice
    Saura, Cristina
    Modi, Shanu
    Kim, Sung-Bae
    Egorov, Anton
    Mathias, Elton
    Cathcart, Jillian
    Cagnazzo, Antonio
    Cheng, Yingkai
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
    Hurvitz, S. A.
    Modi, S.
    Li, W.
    Park, Y. H.
    Chung, W.
    Kim, S-B.
    Cortes, J.
    Yamashita, T.
    Pedrini, J.
    Im, S-A.
    Tseng, L-M.
    Harbeck, N.
    Krop, I.
    Curigliano, G.
    Mathias, E.
    Cathcart, J.
    Cagnazzo, A.
    Ashfaque, S.
    Egorov, A.
    Andre, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336
  • [24] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).
    Li, Bob T.
    Meric-Bernstam, Funda
    Puvvada, Soham D.
    Rowbottom, Jacqui
    Jolliffe, Darren
    Gustavson, Mark
    Mendoza-Naranjo, Ariadna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
    Klempner, Samuel
    Strickler, John
    Gourley, Lindsey
    Jacquemont, Celine
    Bhatia, Vinona
    Hunder, Naomi
    Odegard, Valerie
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
  • [27] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [28] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
    Goto, K.
    Sang-We, K.
    Kubo, T.
    Goto, Y.
    Ahn, M-J.
    Planchard, D.
    Kim, D-W.
    Yang, J. C-H.
    Yang, T-Y.
    Pereira, K. M. C.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Aregay, M.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
  • [29] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
    Smit, E. F. F.
    Li, B. T.
    Mazieres, J.
    Planchard, D.
    Nakagawa, K.
    Goto, K.
    Paz-Ares, L.
    Novello, S.
    Yang, J. C-H.
    Ahn, M-J.
    Liu, G.
    O'Byrne, K.
    Aregay, M.
    Shiga, R.
    Saxena, K.
    Meinhardt, G.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1032 - S1033
  • [30] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
    Janne, Pasi A.
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    De langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345